|
1
|
A phase 2 study of bortezomib in relapsed, refractory myeloma.
|
N Engl J Med
|
2003
|
16.11
|
|
2
|
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
|
J Clin Oncol
|
2006
|
3.60
|
|
3
|
Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.
|
Haematologica
|
2006
|
2.40
|
|
4
|
Long-term outcome results of the first tandem autotransplant trial for multiple myeloma.
|
Br J Haematol
|
2006
|
2.32
|
|
5
|
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.
|
Blood
|
2011
|
2.07
|
|
6
|
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.
|
Blood
|
2005
|
1.95
|
|
7
|
Hyperviscosity syndrome in plasma cell dyscrasias.
|
Semin Thromb Hemost
|
2003
|
1.87
|
|
8
|
Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation.
|
Hematol J
|
2003
|
1.81
|
|
9
|
A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma.
|
Br J Haematol
|
2007
|
1.72
|
|
10
|
Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients.
|
Cancer
|
2007
|
1.65
|
|
11
|
Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.
|
Blood
|
2006
|
1.63
|
|
12
|
A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma.
|
Blood
|
2011
|
1.60
|
|
13
|
Multiple myeloma. Clinical practice guidelines in oncology.
|
J Natl Compr Canc Netw
|
2007
|
1.53
|
|
14
|
Optimizing the CD34 + cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantation.
|
Leuk Lymphoma
|
2009
|
1.50
|
|
15
|
Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
|
Cancer
|
2005
|
1.50
|
|
16
|
NCCN clinical practice guidelines in oncology: multiple myeloma.
|
J Natl Compr Canc Netw
|
2009
|
1.44
|
|
17
|
Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy.
|
Cancer
|
2009
|
1.42
|
|
18
|
Outcome of high-dose cytarabine-based induction therapy followed by hematopoietic stem cell transplantation in acute myeloid leukemia: influence of karyotype.
|
Leuk Lymphoma
|
2008
|
1.39
|
|
19
|
A complete and durable clinical response to high-dose dexamethasone in a patient with scleromyxedema.
|
J Am Acad Dermatol
|
2004
|
1.37
|
|
20
|
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
|
Cancer
|
2005
|
1.36
|
|
21
|
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.
|
Blood
|
2009
|
1.32
|
|
22
|
Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma.
|
J Clin Oncol
|
2009
|
1.28
|
|
23
|
Multiple myeloma.
|
J Natl Compr Canc Netw
|
2011
|
1.28
|
|
24
|
NCCN task force: clinical utility of PET in a variety of tumor types.
|
J Natl Compr Canc Netw
|
2009
|
1.24
|
|
25
|
Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells.
|
Blood
|
2004
|
1.23
|
|
26
|
Hematopoietic growth factors pass through the blood-brain barrier in intact rats.
|
Exp Neurol
|
2007
|
1.21
|
|
27
|
Monoclonal gammopathy of undetermined significance: a consensus statement.
|
Br J Haematol
|
2010
|
1.14
|
|
28
|
Multiple myeloma, version 1.2013.
|
J Natl Compr Canc Netw
|
2013
|
1.14
|
|
29
|
Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter-directed therapy.
|
Blood
|
2012
|
1.13
|
|
30
|
Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw.
|
Lancet Oncol
|
2008
|
1.10
|
|
31
|
Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial.
|
Cancer
|
2006
|
1.05
|
|
32
|
The serum-free light chain assay cannot replace 24-hour urine protein estimation in patients with plasma cell dyscrasias.
|
Blood
|
2007
|
1.04
|
|
33
|
Targeting glucose consumption and autophagy in myeloma with the novel nucleoside analogue 8-aminoadenosine.
|
J Biol Chem
|
2009
|
1.03
|
|
34
|
DNA methylation alterations in multiple myeloma as a model for epigenetic changes in cancer.
|
Wiley Interdiscip Rev Syst Biol Med
|
2010
|
1.03
|
|
35
|
Beneficial effects of hematopoietic growth factor therapy in chronic ischemic stroke in rats.
|
Stroke
|
2007
|
1.01
|
|
36
|
Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma.
|
Blood
|
2005
|
0.99
|
|
37
|
Dual regulation of glucocorticoid-induced leucine zipper (GILZ) by the glucocorticoid receptor and the PI3-kinase/AKT pathways in multiple myeloma.
|
J Steroid Biochem Mol Biol
|
2008
|
0.99
|
|
38
|
Brain repair by hematopoietic growth factors in a rat model of stroke.
|
Stroke
|
2007
|
0.98
|
|
39
|
Bortezomib-induced tumor lysis syndrome in multiple myeloma.
|
Clin Lymphoma Myeloma
|
2006
|
0.97
|
|
40
|
How I treat elderly patients with myeloma.
|
Blood
|
2010
|
0.90
|
|
41
|
First thalidomide clinical trial in multiple myeloma: a decade.
|
Blood
|
2008
|
0.90
|
|
42
|
Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.
|
J Natl Compr Canc Netw
|
2012
|
0.89
|
|
43
|
Expansion of a clonal CD8+CD57+ large granular lymphocyte population after autologous stem cell transplant in multiple myeloma.
|
Am J Clin Pathol
|
2013
|
0.83
|
|
44
|
Authorship limits.
|
N Engl J Med
|
2002
|
0.83
|
|
45
|
Clinical significance of non-Candida fungal blood isolation in patients undergoing high-risk allogeneic hematopoietic stem cell transplantation (1993-2001).
|
Cancer
|
2004
|
0.83
|
|
46
|
Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients.
|
Eur J Haematol
|
2011
|
0.83
|
|
47
|
Granulocyte-colony stimulating factor administration after myocardial infarction in a porcine ischemia-reperfusion model: functional and pathological effects of dose timing.
|
Catheter Cardiovasc Interv
|
2007
|
0.81
|
|
48
|
Multiple Myeloma, Version 2.2016.
|
J Natl Compr Canc Netw
|
2015
|
0.81
|
|
49
|
The role of posttransplantation maintenance chemotherapy in improving the outcome of autotransplantation in adult acute lymphoblastic leukemia.
|
Blood
|
2002
|
0.81
|
|
50
|
Easy to see but hard to find.
|
N Engl J Med
|
2003
|
0.79
|
|
51
|
F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.
|
Br J Haematol
|
2014
|
0.77
|
|
52
|
Regression of cardiac amyloid after autologous stem-cell transplantation.
|
J Heart Lung Transplant
|
2009
|
0.77
|
|
53
|
Chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell transplantation: a little methotrexate goes a long way.
|
J Clin Oncol
|
2002
|
0.77
|
|
54
|
A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings.
|
Clin Adv Hematol Oncol
|
2007
|
0.76
|
|
55
|
Infection--an underappreciated cause of bone pain in multiple myeloma.
|
Br J Haematol
|
2003
|
0.76
|
|
56
|
Conflicts of interest, authorship, and disclosures in industry-related scientific publications.
|
Mayo Clin Proc
|
2010
|
0.75
|
|
57
|
Treatment of multiple myeloma.
|
BMJ
|
2003
|
0.75
|
|
58
|
Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
|
J Natl Compr Canc Netw
|
2017
|
0.75
|
|
59
|
Instability of immunophenotype in plasma cell myeloma.
|
Am J Clin Pathol
|
2008
|
0.75
|
|
60
|
Recent developments and future directions in the treatment of multiple myeloma.
|
Cancer Biother Radiopharm
|
2003
|
0.75
|
|
61
|
Re-use of the original infusional induction chemotherapy as salvage therapy in myeloma patients relapsing after one autograft.
|
Hematology
|
2005
|
0.75
|